IXICO has released results for the 12-months to September 2022, announcing revenues of £8.6m, gross margin of 61%, and EBITDA of £1.5m, in line with our forecasts. Cash at period end was £5.8m. IXICO's order book stood at £16.0m at the end of Sep-22, having signed £12.6m of new contracts through the year. We believe IXICO has successfully re-built its order book, and while the recent trial cessations will continue to impact in FY23E (forecasts maintained), we believe the company is in a strong p ....

07 Dec 2022
Cenkos: IXICO Plc -- Precision in Neuroscience

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: IXICO Plc -- Precision in Neuroscience
IXICO Plc (IXI:LON) | 23.5 -0.1 (-1.1%) | Mkt Cap: 11.4m
- Published:
07 Dec 2022 -
Author:
Chris Donnellan -
Pages:
10 -
IXICO has released results for the 12-months to September 2022, announcing revenues of £8.6m, gross margin of 61%, and EBITDA of £1.5m, in line with our forecasts. Cash at period end was £5.8m. IXICO's order book stood at £16.0m at the end of Sep-22, having signed £12.6m of new contracts through the year. We believe IXICO has successfully re-built its order book, and while the recent trial cessations will continue to impact in FY23E (forecasts maintained), we believe the company is in a strong p ....